

Table 1. Profile of the 10 ABO-Incompatible Cases

| Patient Age/Gender | Primary Disease | Blood Type (Donor/Recipient) | Primary Immunosuppressants | Rejection Therapy | Outcome |
|--------------------|-----------------|------------------------------|----------------------------|---------------------------|---------|
| 5 y/F | BA | A/O | FK, MP, AZ | Pulse, DSG, PE | Alive |
| 1 y/M | BA | AB/B | FK, MP, AZ | Pulse, DSG | Alive |
| 12 y/F | BA | AB/B | FK, MP, AZ | Pulse | Alive |
| 11 m/M | BA | AB/B | FK, MP, AZ | Pulse | Alive |
| 10 y/F | BA | A/B | FK, MP, AZ | Pulse, DSG, PE | Dead |
| 1 y/F | BA | A/O | FK, MP, MMF | Pulse, DSG, PE, rituximab | Alive |
| 42 y/F | PBC | B/O | FK, MP, MMF, rituximab | Pulse, DSG, PE | Alive |
| 10 m/F | BA | A/O | FK, MP, AZ | | Alive |
| 7 m/F | BA | B/A | FK, MP, AZ | | Alive |
| 54 y/F | HCC | A/O | FK, MP, MMF, rituximab | | Alive |

AZ, azathioprine; BA, biliary atresia; DSG, deoxyspergualin; F, female; FK, tacrolimus; HCC, hepatoma; M, male; MMF, mycophenolate mophetil; MP, methylprednisolone; PBC, primary biliary cirrhosis; PE, plasma exchange.

(POD) 3, the titers were high and the LFTs results were elevated despite the PE. On POD 7, a needle biopsy of the graft revealed hyperacute rejection. She was treated with rituximab, deoxyspergualin (DSG), and steroid pulse therapy. A section of the liver biopsy showed erythrocyte sludging in the portal veins, swelling of endothelial cells, and hemorrhagic areas in the periportal areas. Her titers and the LFT results improved drastically; she was discharged on POD 74. Less than 1% CD19-positive lymphocytes were observed in her peripheral blood for 3 months after transplantation. At 2 years and 3 months after transplantation, the girl is in stable condition.

Case 2

A 42-year-old woman, whose primary disease was primary biliary cirrhosis, underwent LDLT with her brother-in-law as the donor (B to O). Because of a high anti-B titer (1:512), she underwent PE 7 times and was administered rituximab as prophylactic therapy just after transplantation. The woman also underwent splenectomy and was administered PGE1 and steroids by intrahepatic artery infusion for 2 weeks. One week after transplantation, the titers elevated and the LFTs showed a slight deterioration; steroid pulse therapy together with PE improved the LFTs. She was discharged on POD 102 due to biliary leakage. CD19-positive lymphocytes in her peripheral blood were less than 1% for over 1 year after transplantation. At 1 year and 5 months after transplantation, the woman is in stable condition.

Case 3

A 54-year-old woman, whose primary disease was LC(B) with HCC underwent LDLT with her son as the donor (A to O). She underwent PE 3 times before transplantation and was administered rituximab as prophylactic therapy just after transplantation. Because her hepatic artery was dissected during transplantation, she was administered PGE1 and steroid by intraportal infusion for 2 weeks and subjected to splenectomy. At 6 month after transplantation, her LFTs are stable with no signs of rejection. CD19-positive lymphocytes in the woman's peripheral blood are less than 1% at 6 months postoperatively.

DISCUSSION

ABO-incompatible liver transplantation has been associated with poor outcomes and should be indicated only for emergency cases. The main reason for these poor results is the severe hyperacute rejection due to antidonor ABO antibodies during the early postoperative period. The impact of preformed antidonor ABO antibodies and the strategy to reduce their titers play key roles in the success of this transplantation.^{1,2} Rituximab has been approved for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. We expected rituximab to reduce complement-dependent and antibody-dependent cellular cytotoxicity induced by antidonor ABO antibodies via B-cells.³ We had good results without using rituximab for children, but the results for adults in terms of humoral rejection have been poor. Therefore, we used rituximab for the adults and for the humoral rejection cases. Furthermore, PE was also expected to directly reduce the titers of anti-ABO antibodies.⁴ We experienced 3 cases of successful ABO-incompatible LDLT by introducing rituximab and PE.

Although rituximab has been used in ABO-incompatible liver transplantation in a limited number of patients,⁵ our results indicate that rituximab and PE may become the new strategy for the ABO-incompatible liver transplantation.

REFERENCES

1. Egawa H, Oike F, Buhler L, et al: Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. *Transplantation* 77:403, 2004
2. Tanabe M, Shimazu M, Wakabayashi G, et al: Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. *Transplantation* 73:1959, 2002
3. Vieira CA, Agarwal A, Book BK, et al: Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. *Transplantation* 77:542, 2004
4. Mor E, Skerrett D, Manzarbeitia C, et al: Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. *Transplantation* 59:986, 1995
5. Monteiro I, McLoughlin L, Fisher A, et al: Rituximab with plasmapheresis and splenectomy in ABO-incompatible liver transplantation. *Transplantation* 76:1648, 2003

Liver Laceration Associated With Severe Seizures After Living Donor Liver Transplantation

Kazushige Sato, Satoshi Sekiguchi, Yorihiro Akamatsu, Naoki Kawagishi, Yoshitaka Enomoto, Takeru Iwane, Akira Sato, Keisei Fujimori, and Susumu Satomi

From the Advanced Surgical Science and Technology Division, Department of Surgery, Graduate School of Medicine, University of Tohoku, Sendai, Japan.

Hemorrhagic complications commonly occur early after liver transplantation (LT), sometimes requiring emergent relaparotomy. However, active bleeding from the liver graft itself is a rare but life-threatening complication after living donor liver transplantation (LDLT). We report an unusual case of liver laceration with massive bleeding, associated with severe epileptic seizures as a result of tacrolimus-induced leukoencephalopathy, after LDLT. The patient was successfully rescued by conventional surgical management without a second transplantation. In conclusion, to our knowledge this is the first reported case of graft rupture due to immunosuppression-associated leukoencephalopathy after LT. *Liver Transpl* 12:152-155, 2006. © 2005 AASLD.

Received July 18, 2005; accepted October 3, 2005.

In spite of significant technical advances, living donor liver transplantation (LDLT) still carries a high incidence of complications. Among the various post-transplant complications, immunosuppression-associated leukoencephalopathy is a well-recognized but uncommon complication. However, the etiology of immunosuppression-associated leukoencephalopathy is uncertain.

Graft rupture after LDLT is also very unusual, and most cases are associated with the handling of the graft during operation.^{1,3,4} The severity of parenchymal injury can range from subcapsular hematoma, with or without active bleeding, to massive disruption. Most cases are salvaged by a second liver graft.¹⁻³ We report what we believe is the first case of liver laceration after LDLT associated with severe generalized tonic-clonic seizures, followed by successful management without a second liver transplantation.

CASE REPORT

The patient, a 14-year-old girl who suffered from biliary atresia, had undergone Kasai's portoenterostomy procedure at Tohoku University Hospital in Sendai, Japan, at 52 days of age. She then suffered several episodes of

esophageal variceal bleeding and biliary tract infection. In August 2003, the patient underwent LDLT using a graft from her 42-year-old mother's left-lobe liver with middle hepatic vein. The patient was 1.54 m tall and weighed 40 kg. The actual donor liver graft weighed 480 g, which corresponded to 50.5% of the recipient's standard liver volume, or 1.14% of her body weight. The total ischemic time from clamping of the portal vein in the donor to portal reperfusion in the recipient was 148 minutes. At the end of the operation, there was neither subcapsular hematoma nor congestion in the liver graft. The graft was then fixed to the abdominal wall with the falciform and round ligaments to prevent rotation of the graft and hepatic outflow block. After closure of the abdomen, Doppler ultrasound showed patency and a normal flow pattern in all vessels with the normal velocity of the portal vein.

Initial immunosuppression consisted of tacrolimus, methylprednisolone, and basiliximab. She was extubated on the first postoperative day. Five days after LT, she had 2 focal seizures consisting of loss of consciousness and decreased oxygen saturation. She developed respiratory failure requiring intubation and was treated with intravenous phenytoin as anticonvulsant therapy.

Abbreviations: LDLT, living donor liver transplantation; LT, liver transplantation.

Address reprint requests to: Kazushige Sato, MD, Advanced Surgical Science and Technology Division, Department of Surgery, Graduate School of Medicine, University of Tohoku, 1-1 Seiryō-cho, Aoba-ku, Sendai 980-8574, Japan. Telephone: 81-22-722-7214; FAX: 81-22-722-7217; E-mail: satokazu@mail.tains.tohoku.ac.jp

DOI 10.1002/lt.20629

Published online in Wiley InterScience (www.interscience.wiley.com).




Figure 1. Schematic view of the lacerations on the bilateral anterior surface of the left liver graft with an expanding subcapsular hematoma along the juncture of the falciform ligament. The 2/0 absorbable sutures using a needle (3.5 cm in diameter) were placed with 40 × 7 mm Teflon felt, including on parenchyma around the bleeding point. The knot was tied to gently squeeze the liver tissue together.

Tacrolimus serum level was 14.8 ng/mL and was discontinued at that point. Brain and abdominal computed tomography shortly after the seizure was normal. Blood flow for the graft was good and no parenchymal abnormality was observed by Doppler ultrasound. Laboratory profiles of the patient were as follows: aspartate aminotransferase, 59 IU/L; alanine aminotransferase, 117 IU/L; prothrombin time, 12.8 seconds (international normalized ratio, 1.60); activated partial thromboplastin time, 27.8 seconds; and platelets, $9.4 \times 10^4/\mu\text{L}$. One day later (posttransplant day 6) she had another severe generalized tonic-clonic seizure lasting several minutes during a magnetic resonance imaging examination. Subsequently, a large amount of fresh blood was observed to be draining from the right subphrenic drainage tube. Tachycardia and hypotension proved refractory to aggressive fluid resuscitation. Resuscitation with blood products was begun, and she was brought to the operating room. During an urgent operation after aspiration of hemorrhagic fluid and evacuation of clots, we found long lacerations on the bilateral anterior surface of the liver graft with an expanding subcapsular hematoma along the juncture of the falciform ligament. The fixation of the graft to the abdominal wall using the falciform and round ligament was divided. There were two lacerations of less than 3 cm in parenchymal depth and about 5 and 7 cm in length, both with active bleeding. Hepatic hemorrhage was controlled temporarily with surgical gauze pads to compress bleeding lesions. However, after abdominal closure, Doppler ultrasonography showed the blood flow in the portal vein decreased and that it remained reversed. Relaparotomy was again performed; after removing the packing, the blood flow in the portal vein was restored without thrombosis. To control bleeding from the liver graft, an alternative surgical procedure was needed; this time, nonabsorbable Teflon felt pledget sutures were placed across the site of the liver



Figure 2. Contrast enhanced computed tomography scan at 35 days after LT shows subcapsular hematoma with nonperfused areas equivalent to 36% of the extended left lobe liver graft.

laceration (Fig. 1). This procedure was repeated until the hemorrhage stopped. The abdomen was closed without fixation of the graft to the abdominal wall. Eighteen units of packed red blood cells were transfused, and large amounts of fresh frozen plasma and several packs of platelets were used during and after the reoperation. Hemoglobin remained stable 4 days postoperatively, but serum aspartate aminotransferase/alanine aminotransferase levels rose to a peak of 1,390/1,634 IU/L after the reoperation and then decreased gradually.

The patient was managed in our surgical intensive care unit with prolonged mechanical ventilation requiring tracheotomy due to methicillin-resistant staphylococcus aureus pneumonia. A computed tomography scan at 35 days after LDLT revealed massive subcapsular hematoma around the falciform ligament (Fig. 2). Fortunately, the patient developed neither biliary complication nor a liver abscess in spite of the prolonged increase in serum bilirubin and persistent coagulopathy.

Three months after LDLT, the patient's liver function returned to a normal range (total bilirubin, 0.9 mg/dL; aspartate aminotransferase, 38 IU/L; alanine aminotransferase, 29 IU/L), and she was discharged from our




Figure 3. Follow-up computed tomography imagings performed 1 year after LT. The subcapsular hematoma has decreased in size with attenuation over time, and it is seen to be completely resolved.

hospital. She remains well with good liver function after 2 years' follow-up, without liver hematoma or necrosis, and with gradually resolving subcapsular lesions (Fig. 3).

DISCUSSION

Active bleeding of a liver graft rupture after LT is an uncommon event. Solimann et al. reported that parenchymal liver injuries in whole LT can be treated with no adverse effect on the patient or graft survival.⁵ However, active bleeding of liver lacerations can lead to a life-threatening event after LDLT.¹⁻³ It has been suggested that the factors responsible for bleeding are portal hypertension due to a small-for-size graft, liver regeneration after partial LT, superficial liver injury during intraoperative manipulation, and preexisting morphologic donor liver abnormality.¹⁻⁴

The fixation of the graft to the abdominal wall is an important technique and is routinely undertaken to avoid hepatic outflow obstruction in left-lobe liver transplant procedures.^{6,7} In our case, the absence of evidence of hematoma or other intrahepatic abnormalities on computed tomography imaging at the first episode of convulsion, suggested that severe generalized tonic-clonic seizure was the cause of the graft rupture.

The mechanism of graft rupture is uncertain but is considered to be a tear of the liver capsule at the juncture of the falciform ligament, which is fixed to the abdominal wall due to contractions of the diaphragm and abdominal muscles. Lacerations along the juncture of the liver graft and the falciform ligament are not frequently involved. Interestingly, only 1 similar case, a result of a falciform ligament tear of the liver secondary to vomiting, has been reported.⁸

Immunosuppression-associated leukoencephalopathy is also a rare complication after LT. Leukoencephalopathy is a complication of tacrolimus or cyclosporine use, and it is usually reversible after discontinuation or dose reduction.^{9,10} In this patient, the neuroradiologic abnormality was bilateral white matter lesions, notably in the parieto-occipital regions. After discontinuation of tacrolimus, a switch to low-dose cyclosporine in combination with mycophenolate mofetil was started after reoperation. Introduction of mycophenolate mofetil was thought useful for low-dose cyclosporine administration to prevent acute rejection and its adverse effects.

To achieve hemorrhage control using conventional surgical methods, there are some techniques such as suture ligation, liver suture, and packing. In this patient, liver sutures with Teflon felt were useful to avoid tearing through the friable parenchyma. If the hemorrhage of this patient could not have been controlled with liver sutures, portocaval shunting would have been a final therapeutic option for achieving hemostasis of the liver. This procedure is a new surgical technique; however, it does necessitate a second liver graft for successful outcomes.¹ In some countries, particularly in Japan, because of the scarcity of available deceased donor organs, the decision to undertake this procedure is made only if conventional surgical techniques have failed to control hemorrhage.

In summary, we presented the successful management of a unique case of liver graft rupture after LDLT associated with severe generalized tonic-clonic seizures due to tacrolimus-related leukoencephalopathy.

REFERENCES

1. Marcos A, Fisher RA, Ham JM, Olzinshi AT, Shiffman ML, Sanyal AJ, et al. Emergency portocaval shunt for control of hemorrhage from parenchymal fracture after adult-to-adult living donor liver transplantation. *Transplantation* 2000; 69:2218-2221.
2. Mistry BM, Solomon H, Garvin PJ, Durham RM, Turnage S, Bacon BR, et al. Spontaneous rupture of the liver upon revascularization during transplantation. *Transplantation* 2000; 69:2214-2218.
3. Ringe B, Braun F, Laabs S, Matamoros M, Lorf T, Canelo R. Graft rupture after living donor liver transplantation. *Transplant Proc* 2002; 34:2268-2271.
4. Kasahara M, Kozaki K, Yoshida T, Yamamoto T, Ogawa K, Ogura Y, et al. Subcapsular hematoma after right-lobe living-donor liver transplantation. *J Hepatobiliary Pancreat Surg* 2004; 11:330-332.
5. Soliman T, Langer F, Puhalla H, Pokoeny H, Grunberger T, Berlakovich GA, et al. Parenchymal liver injury in orthotopic liver transplantation. *Transplantation* 2000; 69:2079-2084.

6. Kubota K, Makuuchi M, Takayama T, Hrihara Y, Watanabe M, Sano K, et al. Successful hepatic vein reconstruction in 42 consecutive living related liver transplantation. *Surgery* 2000;128:48-53.
7. Emond JC, Heffron TG, Whittington PF, Broelsch CE. Reconstruction of the hepatic vein in reduced size hepatic transplantation. *Surg Gynecol Obstet* 1993;176:11-17.
8. Horvath KA, Glasgow AH. Massive intra-abdominal hemorrhage from a hepatic laceration caused by vomiting. *Arch Surg* 1992;127:1361.
9. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. *N Engl J Med* 1996;334:494-500.
10. Torocsik HV, Curless RG, Post J, Tzakis AG, Pearse L. FK506-induced leukoencephalopathy in children with organ transplants. *Neurology* 1999;52:1497-1951.

Experience With Recipient's Superficial Femoral Vein as Conduit for Middle Hepatic Vein Reconstruction in a Right-Lobe Living Donor Liver Transplant Procedure

K. Sato, S. Sekiguchi, T. Fukumori, N. Kawagishi, Y. Akamastu, Y. Enomoto, T. Iwane, K. Fujimori, A. Sato, and S. Satomi

ABSTRACT

Middle hepatic vein reconstruction during the right-lobe living donor liver transplant procedure has been recognized to be a significant factor. We initially reconstructed only a single middle hepatic vein orifice draining into segment 8. In cases where the right-lobe liver graft has several major middle hepatic vein tributaries, including veins draining segment 5 that are remote from the right hepatic vein orifice, a long and thick interposition conduit is necessary for reconstruction. Among 11 consecutive adult patients who received a right-lobe liver graft without a middle hepatic vein at our institution, 8 underwent reconstruction of all major middle hepatic vein tributaries using a vein graft from the recipient's superficial femoral vein. The remaining 3 patients had no major middle hepatic vein tributaries. Posttransplant-computed tomography imagings showed increased liver mass with a patent superficial femoral vein graft in 8 patients. In the absence of a venous system from a deceased donor, a recipient superficial femoral vein offers an excellent size match to maintain the venous outflow of middle hepatic vein tributaries. Reconstruction with recipient superficial femoral vein plays an important role in maximizing liver function and minimizing morbidity in the early posttransplant period.

LIVING donor liver transplantation (LDLT) using a right-lobe liver graft (RLG) is now the standard option for patients with end-stage liver disease. In contrast to an extended right-lobe liver graft including the trunk of the middle hepatic vein (MHV),¹ however, RLG without an MHV trunk can cause serious problems for the recipient owing to congestion in segments 5 and 8. The need for reconstruction of MHV tributaries has been a matter of controversy among transplant surgeons.²⁻⁵

Various vein grafts and technical modifications have been introduced to reconstruct MHV tributaries.^{2-3,5-8} Among a variety of autologous vein grafts, the great saphenous vein (GSV) is commonly utilized for such reconstructive procedures. However, the superficial femoral vein (SFV) is preferable to a GSV graft in terms of caliber and wall thickness.⁹ In our series, we decided to use the recipient's SFV as an interposition vein graft for reconstruction of MHV tributaries. We describe our experience with MHV reconstruction using the recipient's SFV in RLG without an MHV trunk.

PATIENTS AND METHODS

Between April 2003 and March 2004, 11 consecutive LDLT procedures using RLG were performed preserving the main MHV

trunk that drained the remnant left-lobe liver in the donor. The 11 patients included 5 men and 6 women (mean age, 46 years; range, 32-59 years). Of the 11 RLGs, 8 had major MHV tributaries that exceeded 5 mm in diameter. There were no major MHV tributaries in the remaining 3 cases. The 11 total patients were divided into two groups according to presence of major branches of the MHV draining segments 5 and 8: group 1, a RLG with MHV reconstruction using recipient SFV ($n = 8$) and group 2, a RLG without MHV reconstruction due to absence of major MHV tributaries ($n = 3$). The indications for LDLT in this series of patients included fulminant hepatic failure ($n = 4$), primary biliary cirrhosis ($n = 3$), hepatitis B virus with cirrhosis ($n = 1$), adult-onset citrullinemia ($n = 1$), Caroli's disease ($n = 1$), and primary sclerosing cholangitis ($n = 1$). The donors consisted of a child ($n = 3$), spouse ($n = 3$), sibling ($n = 2$), parent ($n = 1$), or other relative ($n = 2$).

From the Department of Surgery, Graduate School of Medicine, University of Tohoku, Sendai, Japan.

Address reprint requests to Kazushige Sato, MD, Advanced Surgical Science and Technology Division, Department of Surgery, Graduate School of Medicine, University of Tohoku, 1-1 Seiryō-cho, Aoba-ku, Sendai 980-8574, Japan. E-mail: satokazu@mail.tains.tohoku.ac.jp

Table 1. Anatomic Variations of Venous Drainage and Estimated Graft Volume in 11 Right-Lobe Grafts

| | Case | Size RHV (mm) | Number of Reconstructions | | GV/SLV (%) | |
|-----------------|------|------------------|---------------------------|-----------------|------------|---------|
| | | | I(M) RHV | MHV Tributaries | 0 | 4 Weeks |
| Group 1 (n = 8) | 1 | 27 | 0 | 2 | 56.4 | 96.0 |
| | 2 | 28 | 0 | 2 | 42.1 | 107.7 |
| | 4 | 29 | 1 | 2 | 52.9 | 86.9 |
| | 5 | 22 | 1 | 2 | 64.9 | 91.0 |
| | 6 | 25 | 0 | 3 | 58.7 | 92.8 |
| | 7 | 23 | 1 | 2 | 52.1 | 94.9 |
| | 9 | 17 | 2 | 2 | 56.7 | 99.8 |
| | 10 | 27 | 1 | 2 | 47.0 | 114.7 |
| | 3 | 38 | 0 | 0 | 59.8 | 91.2 |
| | 8 | 25 | 0 | 0 | 47.7 | 65.6 |
| Group 2 (n = 3) | 11 | 27 | 1 | 0 | 58.5 | 85.7 |

Abbreviations: RHV, right hepatic vein; I(M) RHV, inferior (middle) right hepatic vein; MHV, middle hepatic vein; GV/SLV, ratio of graft volume to recipient standard liver volume.

Donor Operation

In brief, the donor hepatic parenchyma in all cases was transected along the Cantlie line 1 cm to the right of the main MHV trunk without inflow control by Pringle maneuver. The major MHV tributaries and inferior right hepatic vein (IRHV) that exceeded 5 mm in diameter were confirmed by intraoperative ultrasonography and preserved.

Bench Surgery

When the donor graft had major MHV tributaries, the recipient's SFV was harvested for use as an interposition graft. The surgical technique for harvesting the SFV has been described previously.¹⁰ In a basin, all major MHV tributaries were anastomosed to an SFV graft with use of continuous 6-0 prolene suture.

Recipient Operation

Total hepatectomy preserving the IVC was performed after reconstruction of MHV tributaries on the back table. Implantation was done following closure of the stump of the recipient's left hepatic vein. At first, the right hepatic vein (RHV) of the graft was anastomosed to the stump of the recipient's RHV in end-to-end fashion. The SFV interposition graft was anastomosed to the stump of the recipient's MHV using continuous suture. Direct anastomosis of the IRHV to the wall of the recipient's IVC was done in the presence of major IRHV. The graft was reperfused after reconstruction of the portal vein. The hepatic artery anastomosis was performed with microvascular instruments. Biliary reconstruction was accomplished by either choledochojejunostomy using a Roux-en-Y loop or duct-to-duct anastomosis.

RESULTS

The 11 consecutive adult-to-adult LDLT procedures were successful in all cases with a mean follow-up of 17 months (range 11–22 months). Of the 11 patients, 5 underwent liver biopsy due to moderate increases in serum transaminase levels and cholestasis during the first postoperative month. All 5 biopsies had no evidence of typical venous congestion or rejection.

The anatomical variations of all reconstructed hepatic veins in RLG are summarized in Table 1. Reconstruction of hepatic outflow on the back table significantly prolonged the cold ischemic time in group 1 patients (median, 161 minutes; range, 146–452 minutes) compared with that in group 2 patients (median, 74 minutes; range, 74–77 minutes). The warm ischemic time (WIT) for group 1 (median, 56 minutes; range, 40–68 minutes) was longer than that for group 2 (median, 48 minutes, range, 36–56 minutes). However there was no significant difference between the two groups with regard to WIT, which represented the duration of hepatic and portal venous reconstruction.

Although the median peak levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) for group 1 were higher than those for group 2, no patient in either group showed a marked elevation of AST and ALT on postoperative days 14 and 30 (Table 2). Except for one patient (case 10), bilirubin levels were less than 3 mg/dL on postoperative day 14. Changes over time in bilirubin levels were similar for the two patient groups.

Table 2. Postoperative Liver Function Tests of 11 Patients With (Group 1) or Without MHV Reconstruction (Group 2)

| | Peak | | 14 pod | | | 30 pod | | |
|----------------|--------------|--------------|-------------|-------------|---------------|-------------|-------------|---------------|
| | AST (IU/dL) | ALT (IU/dL) | AST (IU/dL) | ALT (IU/dL) | T-Bil (mg/dL) | AST (IU/dL) | ALT (IU/dL) | T-Bil (mg/dL) |
| Group1 (n = 8) | 177 (66–792) | 176 (88–585) | 38 (16–70) | 65 (17–151) | 1.9 (0.9–5.6) | 31 (10–49) | 72 (12–118) | 1.0 (0.6–1.5) |
| Group2 (n = 3) | 97 (83–174) | 146 (53–215) | 33 (21–85) | 51 (17–121) | 1.6 (1.0–3.2) | 23 (22–28) | 66 (50–92) | 1.3 (0.9–1.6) |

Abbreviations: pod, postoperative day; T-Bil, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase. Continuous data are expressed as median and range.




Fig 1. Computed tomographic images obtained 4 weeks after transplantation. (**A, B**) Right-lobe liver grafts with middle hepatic vein (MHV) reconstruction using recipient's superficial femoral vein. The MHV tributaries draining into segments 5 and 8 are shown with arrowheads. (**C, D**) Right-lobe liver grafts without MHV reconstruction due to lack of major MHV tributaries. There was no perfusion defect in the anterior segment in these patients.

The median preoperative ratio of graft volume to recipient standard liver volume (GV/SLV) for group 1 was 54.7% compared with 58.5% for group 2 patients. The median estimated GV/SLV ratio at 4 weeks' postprocedure was 96.5% for group 1 and 85.7% for group 2. A significant difference existed in estimated GV/SLV ratios at 4 weeks' postprocedure between the two groups, but not in the regeneration rate of the anterior and posterior segments. In all 8 patients in group 1, dynamic enhanced-computed tomography (CT) at 4 weeks' postoperation revealed a patent interposition SFV graft (Fig 1A, B). Among the 3 patients in group 2, one patient (case 8) showed relatively poor regeneration at 4 weeks' postprocedure per CT imaging (Fig 1D). This patient was a 35-year-old woman who received a RLG with lack of major MHV tributaries from her 64-year-old father. According to CT volumetry, her liver volume 4 weeks after LDLT was 708 mL, which represented 65.6% of the standard liver volume.

Of the 8 patients in group 1 (all of whom underwent SFV harvesting), 4 (50%) developed transient leg edema without skin changes that was easily managed with graded compression stockings.

DISCUSSION

Reconstruction of hepatic venous outflow is critical in left-lobe or right-lobe LDLT. Hepatic venous outflow impairment has been recognized in right-lobe liver grafts deprived of MHV tributaries. Some patients who did not undergo venous reconstruction developed severe graft dysfunction that resulted in death.¹¹ Although several indications for reconstruction of MHV tributaries have been proposed,^{4,12} we have reconstructed all major MHV tributaries greater than 5 mm. In the current series, postoperative peak values of AST and ALT in cases of RLG with MHV reconstruction indicated that mild hepatic venous congestion was evoked, particularly in the first postoperative week, despite MHV reconstruction. In addition, enzyme values were less than 250 IU/dL in cases of RLG with lack of dominant MHV tributaries, suggesting that outflow from the anterior segment had already developed to drain into the RHV system.¹³ It is impossible to reconstruct all negligible MHV tributaries, no matter how excellent the surgical techniques. Complete MHV replacement in a RLG, however, would not be feasible even if it was deemed necessary. Therefore, it should be noted that the extended right-lobe liver graft is an ideal graft for the recipient with regard to venous outflow of the anterior segment,¹ although the donor may face potential risks.

When there is a necessity for multiple reconstructions of venous outflow, cryopreserved vein graft composites, including common and external iliac veins, may be useful to minimize WIT.⁸ If these techniques, which use cryopreserved vein grafts obtained from a deceased donor, are not available, reconstruction of the MHV must be performed using an autologous vein graft. The GSV is commonly

utilized for such reconstructive procedures, although the GSV is sometimes inadequate for reconstruction of the MHV due to differences in caliber and wall thickness. To overcome these intraoperative dilemmas, Lee and associates³ reconstructed MHV tributaries with two sheets of the GSV. Moreover, experience has shown that recipient left portal vein, even in cases with a patent umbilical portion of the vein, is often inadequate in length as an interposition graft when the major orifice of the MHV branch draining segment 5 is far apart from that of the RHV. Kornberg and associates⁷ described MHV reconstruction using autologous SFV. They reconstructed two major MHV tributaries by using two interposition SFV grafts. We reconstructed all MHV tributaries with a single-vein interposition graft to reduce WIT. Although SFV harvesting has been demonstrated to be a safe procedure in vascular surgery,^{9,10} major concerns remain regarding possible long-term venous morbidity associated with deep-vein removal after liver transplantation.

In summary, a recipient SFV graft is an excellent alternative conduit for MHV reconstruction in the absence of a venous system from a deceased donor.

REFERENCES

- Lo CM, Fan ST, Liu CL, et al: Adult-to-adult living donor liver transplantation using extended right lobe grafts. *Ann Surg* 226:261, 1997
- Ghobrial RM, Hsieh CB, Lerner S, et al: Technical challenges of hepatic venous outflow reconstruction in right lobe adult living donor liver transplantation. *Liver Transpl* 7:551, 2001
- Gyu Lee S, Min Park K, Hwang S, et al: Modified right liver graft from a living donor to prevent congestion. *Transplantation* 74:54, 2002
- Maetani Y, Itoh K, Egawa H, et al: Factors influencing liver regeneration following living-donor liver transplantation of the right hepatic lobe. *Transplantation* 75:97, 2003
- Akamatsu N, Sugawara Y, Kaneko J, et al: Effects of middle hepatic vein reconstruction on right liver graft regeneration. *Transplantation* 76:832, 2003
- Cattral MS, Greig PD, Muradali D, et al: Reconstruction of middle hepatic vein of living-donor right lobe liver graft with recipient left portal vein. *Transplantation* 71:1864, 2001
- Kornberg A, Heyne J, Schotte U, et al: Hepatic venous outflow reconstruction in right lobe living-donor liver graft using recipient's superficial femoral vein. *Am J Transpl* 3:1444, 2003
- Sugawara Y, Makuuchi M, Akamatsu N, et al: Refinement of venous reconstruction using cryopreserved veins in right liver grafts. *Liver Transpl* 10:541, 2004
- Modrall JG, Sadjadi J, Joiner DR, et al: Comparison of superficial femoral vein and saphenous vein as conduits for mesenteric arterial bypass. *J Vasc Surg* 37:36, 2003
- Valentine RJ: Harvesting the superficial femoral vein as an autograft. *Semin Vasc Surg* 13:27, 2000
- Lee S, Park K, Hwang S, et al: Congestion of right liver graft in living donor liver transplantation. *Transplantation* 71:812, 2001
- Sano K, Makuuchi M, Miki K, et al: Evaluation of hepatic venous congestion: Proposed indication criteria for hepatic vein reconstruction. *Ann Surg* 236:241, 2002
- Kaneko T, Kaneko K, Sugimoto H, et al: Intrahepatic anastomosis formation between the hepatic veins in the graft liver of the living related liver transplantation: Observation by Doppler-ultrasonography. *Transplantation* 70:982, 2000

ORIGINAL ARTICLE

Risks of donation and quality of donors' life after living donor liver transplantation

Shigehito Miyagi, Naoki Kawagishi, Keisei Fujimori, Satoru Sekiguchi, Tatsuya Fukumori, Yorihiro Akamatsu and Susumu Satomi

Division of Advanced Surgical Science and Technology, Tohoku University Graduate School of Medicine, Sendai, Japan

Keywords

living-related donor liver transplantation, right lobe.

Correspondence

Shigehito Miyagi MD, PhD, Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, 1-1 Seiryō-machi, Aoba-ku, Sendai 980-8574, Japan. Tel.: +81-22-717-7214; fax: +81-22-717-7217; e-mail: msmsmiyagi@yahoo.co.jp

Received: 26 September 2003;

Revised: 25 June 2004

Accepted: 12 August 2004

doi:10.1111/j.1432-2277.2004.00028.x

Summary

The purpose is to clarify risks of donation and quality of the donor's life after living-related donor liver transplantation (LDLTx). Sixty-eight donors were classified into four groups: lateral segment group ($n = 30$); left lobe group ($n = 18$); left lobe with the middle hepatic vein group ($n = 11$); right lobe group ($n = 9$). We investigated (i) the risks of donation, and evaluated the following: blood loss, operation time, postoperative liver function and duration of hospitalization; (ii) quality of donors' life: donors were mailed a structured questionnaire and the Short-Form Health Survey (SF-36), a generic measure assessing quality of life using eight scales. The results were: (i) there were no differences in liver function and duration of hospitalization between four groups; (ii) 48 donors (71%) responded. All donors returned to normalcy. The donors did not regret their decision to donate except two cases whose recipients had died. The donors' life was almost guaranteed regardless of the lobe we used as the graft.

Introduction

Liver transplantation (LTx) has been established as the standard therapy for end-stage liver disease. But in recent years there is shortage of donors all over the world [1]. To compensate for the shortage of donor grafts, living-related donor liver transplantation (LDLTx) is globally accepted. LDLTx provides potential recipients with timely transplantation, but the procedure is associated with risks to the donor. In LDLTx the donor is exposed to the risks inherent to a surgical operation, and the donor might experience a considerable psychological burden [2]. Therefore, the safety of the donor operation and donors' life after the operation must be guaranteed while maintaining the viability of the graft. For the healthy volunteer donor, classic endpoints (i.e. control of disease, disease-free survival, return to normal activities, etc.) do not apply. For donors, any benefit of donation is primarily a psychological point of view [3,4]. Although the use of grafts from living kidney donors is common, and considerable data exists regarding the psychological impact of

donation [5–7], there are only a few reports about psychosocial outcomes of living liver donors [8–10] except for the reports about donors who provided left lateral segments. There are no reports about the comparison of the psychosocial outcomes of donors who provided left lobe and those who provided right lobe in a single medical centre. Furthermore there are only a few reports, which mentioned about the relationship between the complications of donor or recipients' operation and psychosocial outcomes of donors. The purpose of this study was to clarify the risks of the donor operation and the quality of the donor's life after LDLTx for a long-term.

In our institute we have performed 68 LDLTx from July 1991 to July 2003. We transect the donor liver without using the vascular occlusion technique [11]. We retrospectively reviewed the safety of our donor operations based on parameters such as blood loss, blood transfusion, operation time, duration of hospitalization and complications. In addition, we surveyed our donors' data, which were classified into four groups by the parts of the liver grafts, to learn how they perceived their experience.

Patients and methods

Informed consent was obtained from both donors and recipients. All procedures were reviewed and approved by the ethical committee of Tohoku University School of Medicine and have therefore been performed in accordance with the ethical standards of the Declaration of Helsinki.

Sixty-eight donors for LDLTx received the liver resection in Tohoku University Hospital from July 1991 to July 2003. Age ranged from 17 to 64 years and male:female ratio was 33:35. Their mean age, weight and height were 34.7 ± 8.8 years old, 56.7 ± 7.8 kg and 162.6 ± 8.2 cm, respectively. None of the donors showed abnormal data in blood tests on preoperative assessment. We transected the donor liver without using the vascular occlusion technique [11].

Donors were classified into four groups: (i) lateral segment (LS) group ($n = 30$); (ii) left lobe (LL) group ($n = 18$); (iii) left lobe with the middle hepatic vein (LLM) group ($n = 11$); (iv) right lobe (RL) group ($n = 9$). We investigated (i) the risks at the donor operation and (ii) quality of donors' life at a mean of 1665.3 ± 1113.4 days after donation.

Postoperative complications

Blood loss, blood transfusion, operation time, postoperative liver function, complications and the length of hospitalization were evaluated.

Long-term quality of life of donors after LDLTx

Donors were mailed a structured questionnaire about the general health, present occupational status and 'what you think now about LDLTx' (Table 1). In addition, donors completed the Short Form, 36-question Health Survey (SF-36), a generic measure of quality of life [12,13]. The self-administered SF-36 survey assesses eight health domains: (i) physical functioning, (ii) physical role limits, (iii) emotional role limits, (iv) vitality, (v) pain, (vi) mental health, (vii) social function and (viii) general health.

We also reviewed recipient outcomes (i.e. major complications or death) and analysed the effect of recipient outcome on donors' SF-36 scores.

Statistics

Values are given as mean \pm SD. Student's *t*-test and one-way ANOVA were used to compare categorical data. $P < 0.05$ were considered to be significant. All calculations were made with the StatView software package (SAS Institute, Cary, NC, USA).

Table 1. Structured questionnaire for donors after donation.

1. Are you back at work
 - 1 yes
 - 2 no
2. General health*
 - 1 Good
 - 2 Not so good
 - 3 Bad
 - 4 In the hospital
3. What you think now about LDLTx
 - 1 Not regret
 - 2 Regret

*Are there any new medical symptoms which you relate to the surgery?

Results

Postoperative complications

The weight and height of the donors are given in Table 2. There were no significant differences in weight and height among the four groups, but the average age in the LL and LLM groups was significantly higher than that in the LS group ($P = 0.036$ LL versus LS; $P < 0.001$ LLM versus LS). The weight of the graft in the RL group was significantly more than that in the other three groups (LS, LL, LLM) ($P < 0.001$). The operation time in the LL and LLM groups was significantly longer than that in the LS group ($P = 0.007$ LL versus LS; $P = 0.011$ LLM versus LS) (Table 2).

Blood loss volume in the LLM group was significantly higher than that in the LS and LL groups ($P < 0.001$ LLM versus LS; $P = 0.009$ LLM versus LL). Maximum total bilirubin in the LLM and RL groups was significantly higher than that in the LS group ($P = 0.046$ LLM versus LS; $P = 0.014$ RL versus LS). But maximum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) showed no significant differences among the four groups. There were also no significant differences in the duration of hospitalization among the four groups. Heterologous blood transfusion was not required except for one donor of the LLM group (Table 2).

Postoperative complications occurred in three donors in the LS group, one in the LL group, four in the LLM group and two in the RL group (Table 3). Most postoperative complications were treated without surgical procedure. A donor in the LL group, suffering from sepsis and respiratory distress secondary to the intra-abdominal abscess, was subjected to a drainage operation and was discharged after 64 days of hospitalization. Most of the major complications, such as bile leakage and intra-abdominal abscess occurred at an early period after we started LDLTx. Apart from the donor who had undergone the drainage operation, only several minor complications

Table 2. Age, weight, height, graft weight, operation time, blood loss, postoperative liver function, and hospitalization.

| | LS (n = 30) | LL (n = 13) | LLM (n = 11) | RL (n = 9) |
|----------------------------------|-------------|-------------|--------------|---------------|
| Age (years) | 30.2 ± 6.0 | 37.1 ± 5.3* | 43.0 ± 10.5* | 34.9 ± 11.9 |
| Weight (kg) | 54.9 ± 7.5 | 57.5 ± 6.5 | 61.8 ± 10.0 | 55.2 ± 6.3 |
| Height (cm) | 162.6 ± 7.5 | 162.3 ± 8.7 | 163.3 ± 9.4 | 162.2 ± 9.0 |
| Graft weight (g) | 220 ± 30.1 | 285 ± 46.6* | 372 ± 63.7*† | 553 ± 84.3*†† |
| Operation time (min) | 453 ± 70 | 544 ± 72* | 541 ± 136* | 443 ± 73 |
| Blood loss (ml) | 490 ± 273 | 722 ± 331 | 1201 ± 702*† | 883 ± 346 |
| Heterologous blood transfusion | 0/30 | 0/18 | 1/11 | 0/9 |
| Postoperative liver function | | | | |
| AST Max | 319 ± 247 | 298 ± 170 | 306 ± 178 | 294 ± 104 |
| ALT Max | 393 ± 242 | 334 ± 151 | 412 ± 281 | 291 ± 97 |
| T-bil Max | 1.5 ± 0.6 | 2.5 ± 1.4 | 2.7 ± 1.6* | 2.9 ± 1.1* |
| Mean hospitalization time (days) | 10.9 ± 4.7 | 11.8 ± 13.3 | 14.1 ± 11.4 | 11.2 ± 3.2 |
| Mean follow-up time (days) | 1608 ± 960 | 2347 ± 1095 | 1866 ± 930 | 249 ± 214 |

**P* < 0.05 versus LS group; †*P* < 0.05 versus LL group; ††*P* < 0.05 versus LLM group.

ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Table 3. Complications of donors.

| | LS (n = 30) | LL (n = 13) | LLM (n = 11) | RL (n = 9) |
|-----------------------------------|-----------------|-------------|------------------|-------------|
| Age (years) | 30.2 ± 6.0 | 37.1 ± 5.3* | 43.0 ± 10.5* | 34.9 ± 11.9 |
| Complications | 3/30 | 1/18 | 4/11 | 2/9 |
| Biliary leakage | 2 (cases 2, 44) | 1 (case 6) | 1 (case 4) | 0 |
| Wound infection | 1 (case 2) | 1 (case 6) | 2 (cases 28, 37) | 0 |
| Intra-abdominal abscess | 1 (case 2) | 1 (case 6) | 0 | 0 |
| Sepsis, DIC | 0 | 1 (case 6) | 0 | 0 |
| Prolongation of liver dysfunction | 0 | 0 | 1 (case 4) | 0 |
| Ileus | 0 | 0 | 1 (case 48) | 0 |
| Abdominal wall hernia | 0 | 0 | 0 | 1 (case 62) |
| SMV throm to sis | 0 | 0 | 0 | 1 (case 54) |

**P* < 0.05 versus LS group.

DIC, disseminated intravascular coagulation.

were experienced by other donors. The overall incidence of complications was 13.2% (nine of 68) and that of biliary complication was 5.9% (four of 68). The overall incidence of wound infection was also 5.9% (four of 68). All donors returned to their normalcy within 1 year. There was no donor death in our series (Table 3).

Long-term quality of life of donors after LDLTx

Forty-eight donors (71%) responded at a mean of 1538.2 ± 1194.1 days after donation. But the response rate of donors whose recipients had died was 40.0%. All donors returned to normalcy, and no one was hospitalized (Table 4). Donors did not regret their decision to donate except for two cases whose recipients had died (LS = 1, LLM = 1).

Compared with published Japanese norms (*n* = 3395) [13] in SF-36, our donors scored similar or higher than the general population (Table 5). Donors whose recipients had major complications scored significantly lower on the mental and general health scale than those whose

recipients had no major complications, but those donors still scored as well as the general population on the mental and general health scale. There were no significant differences between the donors who had complications and the donors who had no complications in all eight domains. There were also no significant differences among the four groups (LS, LL, LLM and RL) in all the eight domains.

Discussion

In this study, we retrospectively reviewed the safety of our donor operations based on various parameters. In addition, we surveyed our donors to find out as to how they perceived their experience. As a result, there were no significant differences among the four groups in maximum AST, maximum ALT and the duration of the hospitalization. There were no donor deaths in our series and the safety of donor operation was guaranteed no matter which lobe was used as the graft. Furthermore, in psychosocial outcomes of living liver donors, they did not regret

| | LS (n = 30) | LL (n = 13) | LLM (n = 11) | RL (n = 9) |
|--------------------------------|-------------|-------------|--------------|------------|
| The number of reply | 19 (63.3%) | 13 (72.2%) | 7 (63.6%) | 9 (100%) |
| Mean follow-up time | 1608 ± 960 | 2347 ± 1095 | 1866 ± 930 | 249 ± 214 |
| Present occupational status | 19 (100%) | 13 (100%) | 7 (100%) | 9 (100%) |
| General health | | | | |
| Good | 15 (78.9%) | 12 (84.6%) | 7 (100%) | 9 (100%) |
| Not so good | 3 (15.8%) | 2 (15.4%) | 0 | 0 |
| Bad | 1 (5.3%) | 0 | 0 | 0 |
| In the hospital | 0 | 0 | 0 | 0 |
| What you think now about LDLTx | | | | |
| Not regret | 18 | 13 | 6 | 9 |
| Regret | 1 | 0 | 1 | 0 |

Table 4. Quality of donors' life based on our structured questionnaire.

Table 5. Quality of donors' life based on SF-36 survey.

| | Mental health | Role (emotional) | Social function | Vitality function | Physical | Role (physical) | Bodily pain | General health |
|---------------------------------|---------------|------------------|-----------------|-------------------|-------------|-----------------|-------------|----------------|
| US norm | 74.7 ± 18.1 | 81.3 ± 33 | 83.3 ± 22.7 | 60.9 ± 21 | 84.2 ± 23.3 | 81 ± 34 | 75.2 ± 23.7 | 72 ± 20.3 |
| Japanese norm | 72.7 ± 19.2 | 83.8 ± 31.5 | 86.2 ± 19.4 | 65.3 ± 20.4 | 87.9 ± 15.5 | 85.3 ± 29.0 | 76.2 ± 22.7 | 65.0 ± 19.6 |
| Japanese norm (30–39 years old) | 72.6 ± 17.6 | 86.4 ± 28.8 | 87.1 ± 17.3 | 65.9 ± 19.0 | 92.6 ± 9.6 | 90.5 ± 22.6 | 77.2 ± 21.0 | 67.8 ± 17.0 |
| All donors | 86.4 ± 15.4 | 84.7 ± 26.6 | 93.7 ± 13.1 | 82.5 ± 16.4 | 95.8 ± 5.7 | 86.5 ± 18.6 | 86.2 ± 16.6 | 81.6 ± 17.6 |
| No recipient complications | 88.5 ± 14.1* | 85.4 ± 27.9 | 93.9 ± 13.7 | 83.0 ± 15.7 | 96.5 ± 5.6 | 88.4 ± 18.6 | 86.9 ± 16.9 | 86.8 ± 11.6* |
| Recipients with complications | 74.3 ± 18.0 | 81.0 ± 17.8 | 92.9 ± 9.8 | 79.3 ± 20.9 | 92.1 ± 4.9 | 75.0 ± 14.4 | 82.1 ± 15.8 | 68.6 ± 26.9 |
| No donor complications | 87.1 ± 14.4 | 85.4 ± 26.9 | 93.6 ± 13.7 | 82.9 ± 15.7 | 96.5 ± 5.6 | 87.2 ± 18.6 | 87.3 ± 16.9 | 82.4 ± 16.2 |
| Donors with complications | 82.3 ± 21.3 | 81.0 ± 26.2 | 94.6 ± 9.8 | 80.0 ± 21.0 | 92.1 ± 4.9 | 82.1 ± 18.9 | 79.7 ± 14.1 | 77.3 ± 25.2 |

**P* < 0.05 versus recipients with complications.

their decision to donate except for two cases whose recipients died (LS = 1, LLM = 1) and all donors returned to normalcy within 1 year.

In our institute, the first LDLTx performed was that of an adult to a child in 1991. In 1997, we performed our first adult-to-adult LDLTx. We retrospectively assessed 68 donor operations and found that severe complications had occurred only in the early period after we started LDLTx at our hospital. However, in most cases the donors recovered without the need for surgical treatment. Recent donors developed no major complications. The decrease of donor complications was associated with the improvement of our surgical procedure. Only after one of the donors had undergone drainage operation because of biliary injury, intraoperative cholangiography was performed in all cases, which effectively prevented biliary injuries, decreasing the incidence of major complications. Renz and Roberts [14] reviewed the long-term complications of LDLTx. They reported routine donor hospital stays of less than 10 days; average donor blood losses were approximately 400–800 ml, and the need for heterologous blood transfusion for the donor was uncommon. Moreover, they reported an overall incidence of complications ranging from 15% to 20%. Biliary complications were the most commonly reported source of

donor morbidity with an overall incidence of 5–10%. In the report of Japanese Liver Transplantation Society [15], donor hospital stays were 15.6 days and heterologous blood was given to 21 (1.1%) donors. The incidence of postoperative complications was 12.4% and that of biliary complication, which was also the most commonly complication, was 4.0%. But in the right graft group, the incidence of biliary complications was 10.2%. Compared with these data, donor hospital stays (11 days), average donor blood losses (718.5 ml) and the need for heterologous blood transfusion for the donor were similar in our institution. The overall incidence of complications was 13.2% and that of biliary complication was 5.9%. On the contrary, in the RL group, the incidence of biliary complications was 0%. In our institute there were no significant differences among the four groups in maximum AST, maximum ALT and the duration of hospitalization (Table 3). The safety of donor operation was guaranteed regardless of the lobe we used as the graft.

There has been limited information about psychosocial risks to living liver donors. But in a recent study by Johnson *et al.* [5] on long-term follow-up of 524 living kidney donors using the SF-36 survey, donors reported a better quality of life than the national norm. Generally, published reports on kidney donors indicate that

donors had an improved sense of well-being and self-esteem after donation [5–7]. In our study about psychosocial outcomes of living liver donors, they did not regret their decision to donate except for two cases whose recipients died. All donors returned to normalcy, with no negative impact on social or business interactions.

The results of the SF-36 demonstrated that compared with the published US and Japanese norms in all eight domains measured, the living donors scored well. With regard to general health and mental health, the results highlight the impact of the recipient's course on donor psychosocial outcome after donation (Table 5). The donors whose recipients had major complications scored significantly lower on the mental and general scale than those whose recipients had no major complications. There were no significant differences between the donors who had complications and the donors who had no complications in all the eight domains. In the living kidney donor study by Johnson *et al.* [5] and living liver donor study by Kim-Schluger *et al.* [10] similar results were found. The donors whose recipient died were more likely to say that they would not donate again.

We recognize that our brief survey could not expose some of the deeper and more complex personal issues that affect the quality of life and potential feelings of regret or resentment after donation. In addition, donors were undoubtedly aware that their responses were not anonymous and might in fact be seen by the member of the team responsible for the care of their recipients. We thought that the survey results should be reviewed by independent researchers blinded to the identity of the respondents. But if we adopted this method, it was nearly impossible to classify the groups of donors and to investigate donors' and recipients' complications. So it needs further consideration.

Furthermore we recognized that our study was limited. In fact only 71% of donors responded and 29% of donors did not respond. Moreover the response rate of donors whose recipients had died was only 40.0%. Possible reasons for the lack of response included the fact that some of them moved out and some of them, whose recipients had died, did not want to remember the transplantation. We could not disregard the possibility that these donors might be less satisfied with their experiences.

Living donor LTx has changed the way of the management for the end-stage liver disease. It is a promising option to resolve end-stage liver disease. Safe donor operation allows more patients to receive life-saving liver transplants. However the safety of donors is not 100% guaranteed. So, we must ensure that quality of life after donation remains a primary outcome measure when we consider the utility of LDLTx.

References

1. Harper AM. The OPTN Waiting List, 1988–1999. In: Cecka JM, Terasaki PI, eds. *Clinical Transplants*. Richmond, VA: United Network for Organ Sharing, 2000: 73–83.
2. Kawagishi N, Ohkohchi N, Fujimori K, *et al.* Safety of the donor operation in living-related liver transplantation: analysis of 22 donors. *Transplant Proc* 1998; **30**: 3279.
3. Singer PA, Siegler M, Whittington PF, *et al.* Ethics of liver transplantation with living donors. *N Engl J Med* 1989; **321**: 620.
4. Cronin DC II, Millis JM, Siegler M. Transplantation of liver grafts from living donors into adults: too much, too soon. *N Engl J Med* 2001; **344**: 1633.
5. Johnson EM, Anderson JK, Jacobs C, *et al.* Long-term follow up of living kidney donors: quality of life after donation. *Transplantation* 1999; **67**: 717.
6. Smith MD, Kappel DF, Province MA, *et al.* Living-related kidney donor: a multicenter study of donor education, socioeconomic adjustment, and rehabilitation. *Am J Kidney Dis* 1986; **7**: 223.
7. Simmons RG, Klein SD, Simmons RL. *Gift of Life: The Social and Psychological Impact of Organ Transplantation*. New York, NY: Wiley, 1977.
8. Golman LS. Liver transplantation using living donors. *Psychosomatics* 1993; **34**: 235.
9. Sternek MR, Fischer L, Nischwitz U, *et al.* Selection of the living liver donor. *Transplantation* 1995; **60**: 667.
10. Kim-Schluger L, Florman SS, Schiano T, *et al.* Quality of life after lobectomy for adult liver transplantation. *Transplantation* 2002; **73**: 1593.
11. Ohkohchi N, Sasaki T, Katoh H, *et al.* Coagulability and fibrinolytic changes during veno-venous bypass in liver transplantation. *Tohoku J Exp Med* 1987; **152**: 375.
12. Ware JE. *The SF-36 Health Survey. Manual and Interpretation Guide*. Boston, MA: The Medical Outcomes Trust, 1993.
13. Fukuhara S, Suzukamo Y, Bito S, Kurokawa K. *Manual of SF-36, Japanese version 1.2*. Tokyo: Public Health Research Foundation, 2001.
14. Renz JF, Roberts JP. Long-term complications of living donor liver transplantation. *Liver Transplant* 2000; **6**(Suppl. 2): S71.
15. Umeshita K, Fujiwara K, Kiyosawa K, *et al.* Operative morbidity of living liver donors in Japan. *Lancet* 2003; **362**: 687.

Usage of Deoxyspergualin on Steroid-Resistant Acute Rejection in Living Donor Liver Transplantation

NAOKI KAWAGISHI, KAZUSHIGE SATOH, YOSHITAKA ENOMOTO, YORIHITO AKAMATSU, SATOSHI SEKIGUCHI and SUSUMU SATOMI

Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, Sendai, Japan

KAWAGISHI, N., SATOH, K., ENOMOTO, Y., AKAMATSU, Y., SEKIGUCHI, S. and SATOMI, S. *Usage of Deoxyspergualin on Steroid-Resistant Acute Rejection in Living Donor Liver Transplantation.* Tohoku J. Exp. Med., 2006, 208 (3), 225-233 — Deoxyspergualin (DSG) is an immunosuppressive agent used to treat steroid-resistant acute rejection after kidney transplantation. But in the case of acute rejection after liver transplantation, DSG was reported effective in just a few cases. From July 1991 to November 2005, 96 patients underwent living donor liver transplantation (LDLTx) in our institution. Of them, 9 patients, including 4 ABO incompatible recipients, are presented. Rejection symptoms that did not respond to steroid pulse therapy (methylprednisolone, 10-20 mg/kg/day for 3 days) and were treated with DSG (3 or 5 mg/kg/day) for 4 to 14 days together with a maintenance dose of the steroid. Among them, five responded to treatment with DSG, two did not respond and the other two patients were not evaluated. Six of the nine patients are symptom free at present. Complications such as leukopenia and thrombocytopenia were successfully treated with granulocyte-colony stimulating factor or by platelet transfusion. No recipient died as a direct consequence of the complications induced by DSG. DSG proved effective and safe for some of the LDLTx recipients with steroid-resistant acute rejection but it was not effective for the treatment of accelerated humoral rejection in ABO incompatible recipients. ——— liver transplantation; living donor; deoxyspergualin (DSG); rejection; ABO incompatibility

© 2006 Tohoku University Medical Press

Deoxyspergualin (DSG) was isolated in the 1980's from the *Bacillus laterosporus* found in Japanese fields (Takeuchi et al. 1981). It was initially expected to be an antitumor antibiotic, but it also had special immunosuppressive effects. As for the mechanisms of the immunosuppressive reaction, it was reported that this was not induced by its inhibitory effect on the production of monokines by macrophages or of interleukin-2 by T lymphocytes, but by its cytostatic effect, that is,

the inhibition of the cell cycle at the G0/G1 phase (Nemoto et al. 1987). It also inhibited the maturation of T lymphocytes and the activation, differentiation and maturation of B cells, thereby inhibiting antibody production (Fujii et al. 1990). The immunosuppressive effect of DSG increased with the duration of treatment and DSG was not absorbed from the intestine (Nemoto et al. 1987). Therefore, DSG was recognized as an immunosuppressive agent that could be administered at

Received November 22, 2005; revision accepted for publication December 27, 2005.

Correspondence: Naoki Kawagishi, Division Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan.
e-mail: kawan@mail.tains.tohoku.ac.jp

high doses for a short period. The results of phase I and phase II clinical trials showed that DSG was useful in several situations: (i) prophylaxis and treatment of acute rejection, (ii) prevention of antibody response to biologic agents used for immunosuppression, (iii) suppression of the humoral response at the time of transplantation in sensitized patients, and (iv) inhibition of macrophage-mediated damage of cellular transplantation (e.g., islets) (Wahoff et al. 1996). In a randomized study of DSG vs anti-CD3 monoclonal antibody (OKT3) for the treatment of steroid-resistant acute rejection in renal transplantation, no significant difference in efficacy was found between the two groups (Ohkubo et al. 1993). However, the side effects profile of DSG was significantly better than that of OKT3 (Ohkubo et al. 1993).

In Japan, DSG has been licensed as an immunosuppressive agent for steroid-resistant acute rejection in patients subjected to kidney transplantation since 1994. Thereafter, it was revealed that DSG had novel immunosuppressive effects including the reversion of an established rejection and suppression of the antibody response seen in subsets of sensitized patients (Okazaki et al. 1989). But the efficacy of DSG in patients undergoing liver transplantation is still unknown. Some reports indicated that DSG was effective against acute rejection in sensitized patients as well as in kidney recipients (Kato et al. 1997). In our institution, we have treated 9 LDLTx recipients with DSG for acute cellular and humoral rejection, including 4 patients with ABO incompatibility. In this study, we describe the effects of DSG on steroid-resistant acute rejection in living donor liver transplant recipients.

PATIENTS AND METHODS

Characteristics of the patients

From July 1991 to November 2005, 96 LRLTx were performed in pediatric and adult patients with end-stage liver disease in the Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University. This program was approved by the ethics committees of Tohoku University Hospital and the patients gave their informed consent regarding LDLTx

and the use of DSG for steroid-resistant acute rejection. Donors were selected among parents, brothers or sisters and spouses on the basis of liver function tests, serological markers of hepatitis, ABO blood group, graft/recipient size matching, lymphocyte cross-matching and human leukocyte antigen (HLA) typing. Among them steroid-resistant acute rejection occurred in 9 recipients. The primary diseases of the recipients were biliary atresia in 7, primary sclerosing cholangitis (PSC) in 1, and homozygous familial hypercholesterolemia (FH) in 1. Four recipients were ABO incompatible and 3 out of these 4 recipients were subjected to plasmapheresis (PP) and/or double filtering plasmapheresis (DFPP) because of the high antibody titers they had before transplantation. After transplantation, apheresis was performed to eliminate antibodies in 3 recipients, PP in 2 and PP with continuous hemodiafiltration (CHDF) in 1 (Table 1). In ABO incompatible recipients, an IgM titer of more than 16 was the indication for apheresis. One ABO incompatible recipient was not subjected to apheresis because the antibody titer against donor blood type was low. These 9 recipients consisted of 4 males and 5 females.

Primary immunosuppressive therapy

The immunosuppressive regimen consisted of cyclosporine (CsA), tacrolimus (TAC), azathiopurine (AZ) and methylprednisolone (MP). Seven of the 9 recipients were administered TAC initially while the other 2 were administered CsA. TAC was administered orally 12 hrs before transplantation at a dose of 0.075 mg/kg, and from day 1 after transplantation at a dose of 0.1–0.2 mg/kg/day via a nasogastric tube. On the day of transplantation CsA was administered orally or via a nasogastric tube at a dose of 8 mg/kg/day. The doses of TAC and CsA were adjusted according to plasma trough levels. MP was administered intravenously at a dose of 20 mg/kg/day at the time of the operation and then tapered to 1 mg/kg/day during one week. In the ABO incompatible recipients AZ was administered orally or intravenously from Day 3 before transplantation at a dose of 2 mg/kg/day. In one recipient TAC was switched to CsA because of difficulty in maintaining a suitable trough level.

Rescue therapy for rejection

When symptoms of rejection did not improve with steroid pulse therapy (10–20 mg/kg/day for 3 days), DSG (3 or 5 mg/kg/day) was administered daily for 4 to 14 days together with a maintenance dose of TAC and the

steroid. When the recipient had leukopenia ($WBC < 3,000/mm^3$) or thrombocytopenia ($Plt. < 50,000/mm^3$), granulocyte colony stimulating factor (G-CSF) ($1-2 \mu g/kg$) was administered or platelets were transfused. PP or CHDF was performed if humoral rejection occurred in the ABO incompatible recipients.

Diagnosis of rejection

Protocol liver biopsies were taken at the time of transplantation and after surgery percutaneous fine needle biopsy was performed under ultrasonography when rejection was clinically recognized. Biopsy specimens were formalin-fixed and paraffin-embedded. Five- μm -thick sections were stained with hematoxylin-eosin and Masson's trichrome for collagen. Individual histological features were scored according to a semiquantitative scoring system, which included the following parameters: degree of portal inflammation, piecemeal necrosis, lobular necrosis, steatosis, fibrosis, portal and central vein endothelitis, acute cholangitis, ductular regeneration and cholestasis. Acute ischemic damage was defined by the presence of confluent central or lobular necrosis associated with a variable degree of swelling and bile staining (cholestasis) and without evidence of inflammatory reaction (International Workshop Party 1995). Acute graft rejection was diagnosed by the concomitance of mixed portal inflammation coupled with bile duct inflammation and/or subendothelial inflammation of portal and terminal hepatic veins, according to international criteria (International Workshop Party 1995). Rejection was classified as mild, moderate, or severe.

Monitoring of anti-ABO alloantibodies

The presence of ABO allo-antibodies was assessed in all ABO incompatible patients 2 weeks before transplantation. Serum samples were analyzed with respect to agglutinin titer against a 2 percent suspension in saline of type A or B red blood cells (RBC) after incubation for 1 hour at room temperature. The titer of IgG antibodies was determined by treating the serum samples with 0.01M dithiothreitol (DTT), followed by incubation for 1 hour at 37°C with type A or B RBC. After repeated washings, polyspecific anti-human globulin serum was added. Changes in ABO antibody titers were expressed as the reciprocal number of the highest serum dilution that caused macroscopic agglutination. After transplantation, anti-A or -B alloantibodies were measured every day for the first 7 days and then twice a week.

Apheresis

PP was performed using a continuous blood flow separator (OP-02™ or OP-05™, Asahi Medical Co., Tokyo). As a second filter for DFPP, Evaflex™ (Kuraray Co., Tokyo) was used. CHDF was performed using a high-performance membrane (PANFLO™, Asahi Medical Co.). For a blood access, a double-lumen catheter was placed in the subclavian or femoral vein. Replacement fluids were fresh frozen plasma of AB blood type group or 5% albumin in PP. Nafamostat mesilate (0.15 mg/kg/h) was given as the anticoagulant. PP or DFPP was performed before transplantation on 3 consecutive days in the patients with ABO incompatibility.

RESULTS

Effectiveness for steroid resistant acute rejection

Acute rejection was initially treated with steroid pulse therapy; steroid-resistant acute rejection was occurred once in 9 recipients. They were administered DSG at the dose of 3 or 5 mg/kg/day daily for 4 to 14 days together with the maintenance dose of the steroid (Table 1).

Case 1: The patient was a 5-year-old girl with biliary atresia (BA). She received an ABO incompatible partial liver graft from her mother. Preoperatively PP and DFPP were performed because her anti-A antibody titer was high. On post operative day (POD) 6 liver function tests and histological biopsy indicated acute cellular rejection. She was treated with MP for 3 days. On POD 14 the values of her liver function parameters increased again and the biopsy showed acute cellular rejection. The patient was administered MP followed by DSG at the dose of 3 mg/kg/day for 10 days together with TAC and AZ. PP was also performed to treat her hyperbilirubinemia. After the administration of DSG the value of her liver function parameters decreased and she was discharged on POD 86. During her post operative course no accelerated acute rejection was observed and the anti-A antibody titers decreased after POD 7.

Case 2: The patient was a 1-year-old girl with BA. On POD 6 portal vein thrombosis was detected and thrombectomy was performed under

TABLE 1. Patient demographic characteristics

| No. of Case | Age at Tx/ Gender | P.D. | Blood Type | P.I. | Treatment for Steroid Resistant Acute Rejection | Day on DSG Administration | Outcome |
|-------------|----------------------|------|---------------------|--------------|--|------------------------------|---------------|
| 1 | 5y2m/F | BA | incompatible (A→O) | TAC, AZ, MP | DSG (3 mg/kg/day, 10 days) + PP | 19 POD | effective |
| 2 | 1y5m/F | BA | identical (A→A) | CsA, AZ, MP | DSG (3 mg/kg/day, 4 days) | 13 POD | effective |
| 3 | 11m/M | BA | incompatible (AB→B) | TAC, MP | DSG (3 mg/kg/day, 14 days) + MP | 31 POD | effective |
| 4 | 3y9m/F | BA | identical (A→A) | TAC, MP | DSG (3 mg/kg/day, 7 days) 5 mg/kg/day, 3 days | 464 POD | ineffective |
| 5 | 7y9m/M | BA | identical (O→O) | TAC, MP | DSG (3 mg/kg/day, 4 days) | 1452 POD | effective |
| 6 | 11m/M | BA | identical (B→B) | CsA, AZ, MP | DSG (3 mg/kg/day, 5 days) | 14 POD | effective |
| 7 | 5y11m/M | PSC | identical (B→B) | TAC, MP | DSG (3 mg/kg/day, 9 days) | 26 POD | not evaluated |
| 8 | 10y3m/F | BA | incompatible (A→B) | TAC, AZ, MP | DSG (3 mg/kg/day, 8 days) + splenectomy, PV cannulation, PP, CHDF | 4 POD | ineffective |
| 9 | 2y/F | HFH | incompatible (A→O) | TAC, MMF, MP | DSG (3 mg/kg/day, 10 days) + PP | 5 POD | not evaluated |

P.D., primary disease; P.I., primary immunosuppression; BA, biliary atresia; PSC, primary sclerosing cholangitis; DSG, deoxyspergualin; TAC, tacrolimus; CsA, cyclosporine A; AZ, azathioprine; MP, methylprednisolone; PP, plasma pheresis; CHDF, continuous hemodiafiltration; PV, portal vein; HFH, homozygous familial hypercholesterolemia; MMF, mycophenolate mofetil; POD, post operative day.

laparotomy. The biopsy performed at the same time revealed signs of acute rejection. She was administered MP followed by DSG at the dose of 3 mg/kg/day for 4 days but it was discontinued because of severe leukopenia and thrombocytopenia. Her liver function started to improve on the day after discontinuation of DSG.

Case 3: The patient was an 11-month-old boy with BA (Fig. 1). He received an ABO incompatible partial liver graft from her mother. Apheresis was not performed before surgery because his anti-A antibody was low. On POD 18 the results of liver function tests and biopsy indicated acute cellular rejection. He was treated with MP for 3 days. However, the values of liver function parameters increased again and DSG was administered at the dose of 3 mg/kg/day for 14 days together with a 3-day course of MP pulse therapy. After the administration of DSG the concentration of total bilirubin decreased and he was discharged on POD 78. During his POD course

no accelerated acute rejection was observed and the anti-A antibody titer remained low.

Case 4: The patient was a 5-year-old girl with BA. She had been discharged without any complication after LDLTx at the age of 3. One year after transplantation she developed post-transplant lymphoproliferative disease and her medication was changed from TAC to CsA. Then she developed acute rejection with severe bile duct damage; she was placed under MP pulse therapy followed by DSG at the dose of 3 mg/kg/day for 7 days and 5 mg/kg/day for 3 days. Her liver function improved but not dramatically; thus, she was administered acyclovir because viral hepatitis was also suspected. After these therapies her laboratory and clinical data gradually improved.

Case 5: The patient was an 11-year-old boy with BA. He had undergone LDLTx at the age of 7. He was administered DSG after the second pulse therapy but the values of his liver function




Fig. 1. Rescue therapy by DSG for acute cellular rejection.

Posttransplantation course of case 3. First steroid pulse therapy was ineffective, whereas DSG with MP pulse therapy resulted in improvement of liver function.

DSG, deoxyspergualin; T-Bil, total bilirubin.

parameters were still high after the 4th day on DSG. We speculated this was a case of drug-induced toxicity and withdrew the drug. The biopsy revealed the rejection reaction and drug-induced toxicity had ended. Thereafter his liver function gradually improved.

Case 6: The patient was a 10-month-old boy with BA. On POD 7 the values of liver function parameters and biopsy indicated acute cellular rejection. He was treated with MP for 3 days. However, the values of his liver function parameters increased again and he was administered DSG at the dose of 3 mg/kg/day for 5 days. His liver function improved but his white blood cells count decreased 2 days after the end of the DSG administration and he developed high fever. However, there was no infection and leukopenia improved after treatment with G-CSF.

Case 7: The patient was a 5-year-old boy with PSC. On POD 26 after pulse therapy, he was administered DSG but the value of his liver function parameters were still high after the 5th day on DSG. Examination of a biopsy specimen revealed no signs of rejection but of drug-induced toxicity. DSG was withdrawn on the 9th day of the administration. Thereafter, his liver function gradually improved.

Case 8: The patient was a 10-year-old girl with BA (Fig. 2). She received an ABO incompatible partial liver graft from her mother. Preoperative PP was performed because her anti-A antibody titer was high. On POD 4 the values of liver function parameters and biopsy indicated accelerated acute rejection. She was subjected to PP, splenectomy, MP pulse therapy and DSG. DSG was administered at the dose of 3




Fig. 2. Accelerated acute rejection in case with ABO-incompatible.

Posttransplantation course of case 8. On 4 POD her liver function tests and histological biopsy indicated accelerated acute rejection. She was treated by PP, splenectomy, MP pulse therapy and DSG, however she was not rescued.

PP, plasmapheresis; CHDF, continuous hemodiafiltration; DSG, deoxyspergualin; T-Bil, total bilirubin.